31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

14 July 2026 An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.

Careers

IP Federation elects Philips licensing leader as new president

14 July 2026 Kevin Scott will lead the organisation representing in-house counsel in the UK, for companies such as AstraZeneca, Eli Lilly, MSD and Regeneron.

Biotech

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

13 July 2026 The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time.

More features

‘Blatant imitation’: Indian court blocks copycat pharma branding

Kirkland & Ellis adds leading barrister in London

Kilpatrick adds tech patent litigator and China expert to Chicago office

Litigator from Brown Rudnick moves firms to chair practice

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Arnold & Porter adds tech litigator in San Francisco

Copyright compliance in the life sciences industry

More on this story

Editor's picks

Editor's picks

More features